20 results
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Damage #Pathophys #Peds ... #Genetics #Honc ... #Favism #g6pd #NEJM
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Intermediates and End-Product ... Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
#Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
#Pathophys #Peds ... #Genetics #Honc ... #Favism #g6pd #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
Mortality after Fluid Bolus in African Children with Severe Infection - June 30, 2011 N Engl
NEJMoa1101549 #EBM ... #Peds #Pediatrics ... Boluses #Africa #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis - Kupperman et al. NEJM 2018

https://www.nejm.org/doi/full/10.1056/NEJMoa1716816
Study
Ketoacidosis - Kupperman et ... NEJM 2018 https ... TessaRDavis #EBM ... VisualAbstract #Peds ... Infusion #Rates #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM